Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer

Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer

Introduction: This study aimed to compare the efficacy and safety of docetaxel + trastuzumab + pertuzumab and docetaxel + carboplatin + trastuzumab + pertuzumab for treating HER2-positive breast cancer. Method: HER2-positive breast cancer from patients diagnosed between January 2020 and September 20...

Full description

Bibliographic Details
Main Authors:	Binwei Lin MM, Jinjia Fan MM, Fang Liu MD, Yixue Wen MM, Jie Li MD, Feng Gao MD, Yu Zhang MD, Gang Feng MM, Xiaobo Du MD, Wenzhi Chen MD
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-11-01
Series:	Technology in Cancer Research & Treatment
Online Access:	https://doi.org/10.1177/15330338231218152

Similar Items

Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review
by: Chaokun Wang MS, et al.
Published: (2020-09-01)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
by: Advani P, et al.
Published: (2015-09-01)

Axillary Downstaging and the Impact of Clinical Axillary Status on Efficacy of Neoadjuvant Therapy for HER2-Positive Breast Cancer: A Network Meta-Analysis
by: Yunzhao Luo MM, et al.
Published: (2023-01-01)

Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
by: M. C. Liefaard, et al.
Published: (2024-04-01)

Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer
by: Yifan Xie, et al.
Published: (2021-06-01)

Predictive Markers of Treatment Response to Neoadjuvant Systemic Therapy with Dual HER2-Blockade
by: Soong June Bae, et al.
Published: (2024-02-01)

Adjuvant therapy for HER2 positive pT1a-b pN0 breast cancer
by: Xuan Yang, MM, et al.
Published: (2022-06-01)

Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer
by: Ling-Cheng Wang MD, et al.
Published: (2020-06-01)

Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
by: Cláudia Vieira, et al.
Published: (2023-01-01)

Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)
by: Eriko Tokunaga, et al.
Published: (2021-08-01)

Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer
by: Abdel Kader Y, et al.
Published: (2013-06-01)

Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland
by: Agnieszka Irena Jagiełło-Gruszfeld, et al.
Published: (2022-02-01)

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
by: Fara Brasó-Maristany, et al.
Published: (2020-01-01)

Analysis of the Effect of Trastuzumab Combined with Docetaxel on Serum Tumor Markers in the Treatment of HER-2 Positive Breast Cancer and Factors Influencing Therapeutic Efficacy
by: Feng QZ, et al.
Published: (2021-10-01)

Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer
by: Alexis LeVee, et al.
Published: (2023-05-01)

Features of response to modern neoadjuvant chemotherapy with dual anti-HER2 blockade (trastuzumab and pertuzumab) in the patients with HER2-positive breast cancer stage II–III
by: Dmitriy A. Morozov, et al.
Published: (2021-12-01)

Immune microenvironment dynamics of HER2 overexpressing breast cancer under dual anti-HER2 blockade
by: Sofia Batalha, et al.
Published: (2023-10-01)

Dual anti-HER2 blockade in late-line treatment of metastatic HER2-positive breast cancer
by: M. A. Frolova, et al.
Published: (2021-12-01)

Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer
by: Yi Xiao, et al.
Published: (2022-05-01)

Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
by: Ji Young You MD, et al.
Published: (2023-11-01)

Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
by: Zheng-Jun Yang, et al.
Published: (2024-01-01)

Examining Cardiotoxicity With HER2 Therapies∗
by: Neelima Denduluri, MD
Published: (2020-06-01)

Neoadjuvant Trastuzumab Concurrent with Nonanthracycline-based Regimens for HER2-positive Locally Advanced Breast Cancer
by: Wei-Hsin Liu, et al.
Published: (2014-09-01)

Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP
by: Jung Hwan Ji, et al.
Published: (2023-01-01)

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
by: Giulia Bon, et al.
Published: (2020-12-01)

Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review
by: Wei Wang MM, et al.
Published: (2023-05-01)

The Effectiveness of Lapatinib in HER2-Positive Metastatic Breast Cancer Patients Pretreated With Multiline Anti-HER2 Treatment: A Retrospective Study in China
by: Xinzhao Wang MD, et al.
Published: (2021-08-01)

Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?
by: Angela Dalia Ricci, et al.
Published: (2021-11-01)

Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer
by: Nalee Kim, et al.
Published: (2023-12-01)

Differences between the efficacy of HER2(2+)/FISH-positive and HER2(3+) in breast cancer during dual-target neoadjuvant therapy
by: Wei Chen, et al.
Published: (2023-10-01)

Educational Case: HER-2 Positive Breast Cancer
by: Julia Jennings MD, et al.
Published: (2021-09-01)

The efficacy and safety of dual HER2 blockade with a pertuzumab-based regimen for metastatic breast cancer patients previously exposed to an anti-HER2 agent: a systematic review and meta-analysis
by: S. Chen, et al.
Published: (2021-04-01)

Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer
by: Andrea Rocca, et al.
Published: (2021-02-01)

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
by: Nindo B. Punturi, et al.
Published: (2021-05-01)

Network Meta-Analysis of Chinese Herbal Injections Plus the FOLFOX Regimen for the Treatment of Colorectal Cancer in China
by: Dan Zhang MM, et al.
Published: (2019-02-01)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
by: E. Von Cheong, et al.
Published: (2021-04-01)

Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells
by: Demet Candas-Green, et al.
Published: (2020-09-01)

P123 Optimal Regimen of Neoadjuvant Systemic Therapy for HER2 Positive Early Breast Cancer
by: C. Lo, et al.
Published: (2023-03-01)

Follow-Up at 2 years After Emergency Surgery for Constrictive Pericarditis Complicated With Gastrointestinal Bleeding
by: Xu Zhao MM, et al.
Published: (2022-01-01)

Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab
by: Fanfan Li, et al.
Published: (2022-03-01)